Title
Therapeutic CPAP Level Predicts Upper Airway Collapsibility in Patients With Obstructive Sleep Apnea.

Permalink
https://escholarship.org/uc/item/6189897x

Journal
Sleep, 40(6)

ISSN
0161-8105

Authors
Landry, Shane A
Joosten, Simon A
Eckert, Danny J
et al.

Publication Date
2017-06-01

DOI
10.1093/sleep/zsx056

Peer reviewed
Therapeutic CPAP Level Predicts Upper Airway Collapsibility in Patients With Obstructive Sleep Apnea

Shane A. Landry, PhD1;2; Simon A. Joosten, MD PhD1,4,5; Danny J. Eckert, PhD1;7; Amy S. Jordan, PhD1,8,9; Scott A. Sands, PhD1,10; David P. White, MD2; Atul Malhotra, MD11; Andrew Wellman, MD PhD6; Garun S. Hamilton, MD PhD8,9; Bradley A. Edwards, PhD1,2,8

1Sleep and Circadian Medicine Laboratory, Department of Physiology, Monash University, Melbourne, Victoria, Australia; 2School of Psychological Sciences and Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Melbourne, Victoria, Australia; 3Monash Lung and Sleep, Monash Medical Centre, Clayton, Victoria, Australia; 4School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia; 5Monash Partners - Epworth, Melbourne, Australia; 6Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; 7Neuroscience Research Australia (NeuRA) and the University of New South Wales, Randwick, Sydney, New South Wales, Australia; 8Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Australia; 9Institute for Breathing and Sleep, Heidelberg, Victoria, Australia; 10Department of Allergy, Immunology and Respiratory Medicine and Central Clinical School, The Alfred and Monash University, Melbourne, Victoria, Australia; 11Division of Pulmonary and Critical Care Medicine, University of California San Diego, CA

Study Objectives: Upper airway collapsibility is a key determinant of obstructive sleep apnea (OSA) which can influence the efficacy of certain non-continuous positive airway pressure (CPAP) treatments for OSA. However, there is no simple way to measure this variable clinically. The present study aimed to develop a clinically implementable tool to evaluate the collapsibility of a patient’s upper airway.

Methods: Collapsibility, as characterized by the passive pharyngeal critical closing pressure (Pcrit), was measured in 46 patients with OSA. Associations were investigated between Pcrit and data extracted from patient history and routine polysomnography, including CPAP titration.

Results: Therapeutic CPAP level, demonstrated the strongest relationship to Pcrit (r=0.51, p < .001) of all the variables investigated including apnea-hypopnea index, body mass index, sex, and age. Patients with a mildly collapsible upper airway (Pcrit ≤ −2 cmH2O) had a lower therapeutic CPAP level (6.2 ± 0.6 vs. 10.3 ± 0.4 cmH2O, p < .001) compared to patients with more severe collapsibility (Pcrit > −2 cmH2O). A therapeutic CPAP level ≤8.0 cmH2O was sensitive (89%) and specific (84%) for detecting a mildly collapsible upper airway. When applied to the independent validation data set (n = 74), this threshold maintained high specificity (91%) but reduced sensitivity (75%).

Conclusions: Our data demonstrate that a patient’s therapeutic CPAP requirement shares a strong predictive relationship with their Pcrit and may be used to accurately differentiate OSA patients with mild airway collapsibility from those with moderate-to-severe collapsibility. Although this relationship needs to be confirmed prospectively, our findings may provide clinicians with better understanding of an individual patient’s OSA phenotype, which ultimately could assist in determining which patients are most likely to respond to non-CPAP therapies.

Keywords: Obstructive sleep apnea, CPAP, phenotyping, collapsibility, Pcrit

INTRODUCTION

Although it is well recognized that patients with obstructive sleep apnea (OSA) have a more collapsible upper airway compared to healthy controls,1 recent evidence has highlighted a number of nonanatomical factors that also contribute to airway collapse. These include a hypersensitive ventilatory control system,2 an ineffective upper airway dilator muscle response,3 and a low respiratory arousal threshold.4 These traits vary substantially between patients, such that OSA can manifest from a number of different physiological mechanisms. Such variability in the OSA phenotype may therefore explain the variable efficacy of the current non-CPAP therapies for treating OSA. Importantly, emerging evidence demonstrates that people with OSA with less severe upper airway collapsibility are more likely to respond to therapies targeting both anatomical (ie, oral appliances5 and weight loss6) and nonanatomical causes of OSA (ie, oxygen/sedatives7). It should be noted, however, that this has not been found to be the case for all CPAP-alternative treatments.8,9 One of the major hurdles to adopting a personalized approach to treating OSA is the lack of clinically implementable physiological screening tools. Currently, methods for quantifying the degree of upper airway collapsibility require specialized equipment and technically difficult methodologies. As such, there is a need to establish simplified ways of determining this pathophysiological information to allow personalized treatment approaches to be implemented in the clinic. Therefore, the current study aimed to develop a method of determining upper airway collapsibility using routinely collected clinical information from a patient’s history or from clinical polysomnography (PSG) or CPAP titration.

METHODS

Participants

We analyzed data from 60 people with OSA who participated in studies conducted in sleep laboratories at the Brigham and Women’s Hospital and Monash University. Participants were
recruited through the general community and at sleep clinics at either site. All patients were screened and excluded if they had a history of renal failure, neuromuscular disease, neurological disorders, central sleep apnea, uncontrolled diabetes, heart failure, thyroid disease, or any other uncontrolled medical condition. Patients were also excluded if they were taking any medications known to affect sleep, ventilation, or muscle control. Forty-two (70%) of these patients had been regularly receiving treatment (either via CPAP or an oral appliance) before study enrolment but were not required to abstain from treatment before study procedures. Written informed consent was provided before enrolment, which was approved by the local ethics committees.

Experimental Protocol
At each of the sites, participants underwent an in-laboratory clinical PSG to confirm the presence and severity of OSA (defined by apnea-hypopnea index [AHI] >10 events/hour) and a research PSG to measure the OSA traits (including upper airway collapsibility). For the clinical PSG, a standard clinical montage recorded electroencephalogram (EEG), electrooculogram, chin and leg electromyogram, electrocardiogram, nasal pressure, nasal/oral thermistor, thoracic and abdominal respiratory effort, and arterial oxygen saturation. Sleep staging, arousals, and respiratory events were scored according to standard criteria. During the research PSG, in addition to the standard clinical montage, patients slept with a nasal mask which facilitated the measurement of airflow via a pneumotachometer (Hans Rudolph, Kansas City, Missouri), mask pressure (Validyne, Northridge, CA), and CO₂ (Vacumed, Ventura, California). CPAP was delivered by a device capable of delivering both positive and negative pressure (+20 cmH₂O to −20 cmH₂O) as well as near instantaneously switching between two pressure levels (Philips-Respironics, Murrysville, Pennsylvania).

Determining Therapeutic CPAP Level
During supine non-rapid eye movement (NREM) sleep, CPAP level was titrated to a level sufficient to eliminate apnea, hypopnea, snoring, and inspiratory flow limitation (ie, therapeutic CPAP level). The step size (in cmH₂O) and the time interval between individual increases in CPAP level was left to the discretion of the titrating researcher but was no greater than 1 cmH₂O per minute of sleep. The therapeutic CPAP level was reassessed multiple times during the research PSG by reducing CPAP to a confirmed subtherapeutic pressure and retitrating until respiratory events and flow limitation were again resolved.

Measuring Upper Airway Collapsibility
Passive upper airway critical closing pressure (Pcrit) was measured during the research PSG to assess upper airway collapsibility using standard techniques. Briefly, stepwise reductions in the CPAP from the therapeutic level for five breaths were performed until apnea was produced during stable supine NREM sleep. Linear regressions were performed between the peak inspiratory airways and mask pressure for breaths three to five (if the breaths were flow limited) after each CPAP drop. The x intercept of the peak inspiratory airflow versus mask pressure regression (zero flow crossing) was taken as the Pcrit. Multiple series of these stepwise CPAP reductions were conducted throughout the sleep period, each yielding a measurement of the participant’s Pcrit. Each individual’s Pcrit measurements were then averaged to provide a single Pcrit value for each participant.

Data and Statistical Analysis
A “development” data set (n = 60) consisting of physiological (Pcrit), clinical (AHI, therapeutic CPAP), and anthropometric (age, sex, body mass index [BMI]) data was examined for variables capable of accurately predicting upper airway collapsibility. In the studies in which a treatment intervention was tested, only data from the baseline/placebo conditions were used. Using univariate regression, the development data set was examined for associations between Pcrit and the anthropometric/clinical variables described above to determine the best predictors. To control for colinear interactions, a multivariate linear regression was then performed incorporating all independent variables to determine which predictors remained significant. Hierarchical multiple regression was performed to determine whether a multivariate model provided a better prediction than any of the single predictors. A binary classification was used to differentiate patients with a mildly collapsible airway (defined by Pcrit ≤ −2 cmH₂O) from a moderate-severely collapsible airway (defined as a Pcrit > −2 cmH₂O) based on previously published data. Receiver operating characteristic (ROC) curves were then calculated to determine the best threshold values (based on sensitivity and specificity) that differentiated patients' groups based on these collapsibility categories.

Those variables determined in the development data were then tested by assessing their accuracy against an independent (“validation”) data set (n = 75) collected as part of a previously published physiological study with a similar number of patients. Sensitivity, specificity, positive, and negative predictive values were compared between the development and validation data set.

RESULTS
Of the 60 participants included in the development analysis, successful Pcrit measurements were obtained in 46 patients (77%). The validation data set included 75 participants, 74 (99%) of whom had successful Pcrit measurements. Demographic and anthropometric information for both groups is presented in Table 1.

Associations Between Pcrit and Demographic and Polysomnographic Indexes
In the development data set, no significant associations were found between Pcrit and BMI, age, or male sex, see Figure 1. A significant association was found between Pcrit and AHI (r² = 0.19, p = .002). Of each of the variables investigated, therapeutic CPAP level demonstrated the strongest relationship to Pcrit (r² = 0.51, p < .001), see Figure 2.

Multivariate linear regression (including therapeutic CPAP, AHI, BMI, age, and sex as independent variables) demonstrated that therapeutic CPAP level and AHI remained the only independent predictors of Pcrit(r² = 0.57, p < .001, adjusted r² = 0.52). When assessed against the simple regression including only therapeutic CPAP level, this multivariate model did not
Therapeutic CPAP Predicts Upper Airway Collapsibility—Landry et al.

significantly improve the prediction of $P_{\text{crit}}$ ($r^2$ change $= 0.07$, $F_{[4,40]} = 1.51$, $p = .218$), see Table 2. We therefore decided to test the predictive value of the simplest (most parsimonious) model (therapeutic CPAP level alone) for estimating upper airway collapsibility.

Determining Upper Airway Collapsibility From Therapeutic CPAP Level

In the development data set, patients with a mildly collapsible upper airway ($P_{\text{crit}} \leq -2$ cmH$_2$O) had a significantly lower therapeutic CPAP level compared to the more collapsible group ($P_{\text{crit}} > -2$ cmH$_2$O; $t_{(44)} = 4.41$, $p < .001$), see Figure 3. ROC curve analysis using therapeutic CPAP level as the testing variable to predict $P_{\text{crit}}$, showed a significant area under the curve (AUC) of 0.91 ± 0.07 ($p < .001$). The best sensitivity/specificity trade-off was found for therapeutic CPAP levels between 6.0 and 8.0 cmH$_2$O. A therapeutic CPAP level of $\leq 6.0$ cmH$_2$O provided a sensitivity of 86% (CI: 78%–98%), that is, CPAP level $> 6.0$ cmH$_2$O correctly predicted a $P_{\text{crit}} > -2$ cmH$_2$O 92% of the time. By comparison, a therapeutic CPAP level of less than or equal to 8.0 cmH$_2$O provided a sensitivity of 89% (CI: 51%–99%) and a specificity of 84% (67%–93%). PPV was 57% (CI: 30%–81%) and NPV was 97% (CI: 83%–99%). Importantly, those individuals misclassified as having a mildly collapsible airway using these CPAP level thresholds (ie, false positives) still tended to have negative $P_{\text{crit}}$ values ($\leq 6$ cmH$_2$O: −1.5 cmH$_2$O, $\leq 7$ cmH$_2$O: −0.8 ± 0.4 cmH$_2$O, $\leq 8$ cmH$_2$O: −0.3 ± 0.5 cmH$_2$O). Sensitivity and specificity values for each CPAP level (between 4.0 and 16.0 cmH$_2$O) are provided in the online Supplementary Material.

Assessing the Accuracy of Therapeutic CPAP Level to Predict Upper Airway Collapsibility in an Independent Data Set

In the independent (validation) data set, therapeutic CPAP level was also strongly associated with $P_{\text{crit}}$ ($r^2 = 0.54$, $p < .001$), and ROC curve analysis demonstrated a similarly high AUC of 0.88 ± 0.05 ($p < .001$). See online Supplementary Material for comparison plots between the development and validation data sets. The therapeutic CPAP level cutoff values

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Development data set ($n = 46$)</th>
<th>Validation data set ($n = 74$)</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>30 males:16 females</td>
<td>49 males:25 females</td>
<td>.91</td>
</tr>
<tr>
<td>Age (years)</td>
<td>50.8 ± 12.0</td>
<td>44.7 ± 11.6</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>33.8 ± 7.9</td>
<td>33.0 ± 6.7</td>
<td>.55</td>
</tr>
<tr>
<td>AHI (events/hour)</td>
<td>40.8 [43.4]</td>
<td>29.3 [45.4]</td>
<td>.01</td>
</tr>
<tr>
<td>Therapeutic CPAP (cmH$_2$O)</td>
<td>9.5 ± 3.0</td>
<td>9.4 ± 3.5</td>
<td>.92</td>
</tr>
<tr>
<td>$P_{\text{crit}}$ (cmH$_2$O)</td>
<td>0.2 ± 3.3</td>
<td>-1.5 ± 4.9</td>
<td>.04</td>
</tr>
</tbody>
</table>

AHI = apnea-hypopnea index; BMI = body mass index; CPAP = continuous positive airway pressure. Mean ± standard deviation, or median [interquartile range] are shown.
of 6.0–8.0 cmH₂O maintained good predictive accuracy for determining the degree of upper airway collapsibility (Table 3). The specificity and PPV improved (at the expense of reduced sensitivity and NPV) relative to the development data set.

DISCUSSION

The major finding of our study is that an OSA patient’s therapeutic CPAP requirement provides key information about the collapsibility of their upper airway. Lower therapeutic CPAP levels are associated with more negative P_{crit} (less collapsible) values. Specifically, patients with a CPAP requirement below 6–8 cmH₂O were highly likely to have a mildly collapsible upper airway (defined by a P_{crit} ≤ −2 cmH₂O). Importantly, when applied to a separate validation data set, the therapeutic CPAP thresholds we established predicted mild upper airway collapsibility with high specificity and PPV. Although, the association between these variables may seem intuitive, the current findings highlight for the first time the strength and predictive utility of this relationship. In a clinical context, this information could potentially be used by physicians to distinguish between patients in whom a highly collapsible upper airway is a dominant factor contributing to OSA, from those where the upper airway is only mildly collapsible (but abnormalities in one or more nonanatomical traits could be a major causative factor).

Relationship Between P_{crit} and Therapeutic CPAP Level

The present study found a strong positive association between therapeutic CPAP levels and P_{crit} in both our development (r² = 0.51) and validation data (r² = 0.54). This contrasts with previous work by Sforza et al., who found only a weak association between these variables (r² ~ 0.07). This discrepancy is likely due to the fact that Sforza et al. measured P_{crit} under active neuromuscular conditions, and thus, any associations between P_{crit} and therapeutic CPAP level would have been confounded by individual variability in upper airway muscle responsiveness. By contrast, our measurements of P_{crit} assessed collapsibility of the upper airway under relatively passive neuromuscular conditions (ie, passive P_{crit}).

A positive association between passive P_{crit} and therapeutic CPAP makes intuitive sense when one considers how these variables are defined and measured. P_{crit} represents the mask pressure at which the upper airway collapses. The therapeutic CPAP level represents the minimal mask pressure capable of producing nonflow limited (eupneic) ventilation. At mask pressures lower than therapeutic CPAP level, peak inspiratory flow reduces in a linear fashion until flow becomes zero (ie, P_{crit} is reached). In this way, more positive P_{crit} values should be associated with a higher CPAP level required to resolve flow limitation (ie, therapeutic CPAP), similarly more negative P_{crit} would be expected to require lower CPAP levels. By extrapolating pressure/flow dynamics from published data in controls, snorers, and people with OSA to a starling resistor model of the upper airway, Gold and Schwartz similarly predicted that a pressure difference of 8 cmH₂O would exist between the holding pressures of the upper airway. Gold and Schwartz similarly predicted that a pressure difference of 8 cmH₂O would exist between the holding pressures of the upper airway.

Table 2—Comparison of Linear Regression Models for Determining P_{crit}.

<table>
<thead>
<tr>
<th>Variable</th>
<th>β</th>
<th>SE of β</th>
<th>β Std</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simple model</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic CPAP level</td>
<td>0.82</td>
<td>0.12</td>
<td>0.71</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Multivariate model</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic CPAP level</td>
<td>0.76</td>
<td>0.13</td>
<td>0.66</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>AHI</td>
<td>0.03</td>
<td>0.01</td>
<td>0.28</td>
<td>.02</td>
</tr>
<tr>
<td>BMI</td>
<td>−0.04</td>
<td>0.06</td>
<td>−0.09</td>
<td>.54</td>
</tr>
<tr>
<td>Age</td>
<td>−0.01</td>
<td>0.04</td>
<td>−0.04</td>
<td>.78</td>
</tr>
<tr>
<td>Male sex</td>
<td>−0.14</td>
<td>0.77</td>
<td>0.02</td>
<td>.86</td>
</tr>
</tbody>
</table>

Data from the development data set are shown. AHI = apnea-hypopnea index; BMI = body mass index; CPAP = continuous positive airway pressure; β = beta efficient; β Std =standardized beta efficient; SE = standard error.

Figure 2—Clinical predictors of P_{crit}. Univariate linear regressions demonstrated (A) therapeutic CPAP level to be the strongest predictor of P_{crit} (r² = 0.51, p < .001) and to a lesser extent (B) apnea-hypopnea index (r² = 0.19, p = .002). Data from the development data set are shown. CPAP = continuous positive airway pressure.

SLEEP, Vol. 40, No. 6, 2017

Therapeutic CPAP Predicts Upper Airway Collapsibility—Landry et al.
pressure (therapeutic CPAP) and P\text{crit}. Our observed data confirm this modeled relationship, although we found a slightly wider average differential between P\text{crit} and the therapeutic CPAP level (median = 8.8, interquartile range [IQR] = 2.6). For this simple relationship between P\text{crit} and therapeutic CPAP level to exist in our group data, it suggests that reductions in inspiratory flow for any given reduction in mask pressure (ie, the slope of the flow/mask pressure relationship) are similar between individuals. Conversely, our data suggest that the slope of this relationship demonstrates a mild positive association with P\text{crit}, and that those with greater collapsibility have a significantly steeper gradient to this flow/pressure relationship (see Supplementary Material). This indicates that below the therapeutic CPAP level, small stepped reductions in mask pressure tend to result in lesser reductions in peak flow in those with mild collapsibility, whereas in those with more severe collapsibility, the same reductions in mask pressure tend to result in more significant collapse of the airway, resulting in greater reductions in peak inspiratory flow. Such variation in the slope of the flow/pressure relationship may be related to the mechanism or site of upper airway collapse, although this warrants further investigation.

### Relationship Between P\text{crit} and Demographic/Anthropometric Variables

Contrary to previous investigations,\textsuperscript{15,16-18} the present study did not find a statistically significant association between P\text{crit} and BMI nor did we find any difference in P\text{crit} between males and females. However, the previous documented associations between BMI and P\text{crit} have been found to be relatively weak (r\textsuperscript{2} \sim 0.10-0.14), and in some cases, these associations have included patients as well as healthy controls (ie, non-OSA patients).\textsuperscript{16} Such associations must be interpreted with care as they may not necessarily be as predictive within an OSA only cohort such as that used in the present study. The magnitude of reported sex differences in P\text{crit} have varied substantially between studies (0.5–1.8 cmH\text{O}) but has tended to be small or only significant in groups matched for BMI.\textsuperscript{18} Importantly, with regard to the present analysis, for such variables to be useful clinical predictors of upper airway collapsibility, not only must they share a statistically significant association, the association must be strong and account for a large amount of variability in P\text{crit}. In the present data, the only variable that fit this criterion was therapeutic CPAP level.

### OSA Pathophysiology: Importance of Upper Airway Collapsibility

The present findings support to the concept that the therapeutic CPAP level could be used to identify which patients with OSA have a P\text{crit} < −2 cmH\text{O}, indicating that they have an airway which is only mildly collapsible. In a recent study, designed to identify the pathophysiological causes of OSA in a large cohort of patients, Eckert et al.\textsuperscript{12} found that 19% of people with OSA studied had mild upper airway collapsibility (defined by a P\text{crit} < −2 cmH\text{O}), a proportion consistent with that found in our development data set (9/46, 20%) as well as other physiological investigations.\textsuperscript{19} Importantly, Eckert found that 100% of such patients had abnormalities in one or more of the nonanatomical traits also known to cause OSA (ie, ineffective upper airway muscles responsiveness, hypersensitive ventilatory control, or a low respiratory arousal threshold). Of note was the finding that many control participants were found to have similar airway collapsibility to patients with OSA but did not have OSA, likely due to the absence of these nonanatomical abnormalities. Consistent with this finding, Patil et al.\textsuperscript{19} reported that all people with OSA they studied had P\text{crit} values greater than −5 cmH\text{O} but above this threshold found a similar degree of overlap in airway collapsibility between people with OSA and roughly half of their non-OSA control participants. The key factor differentiating individuals in this area of overlap was that the controls had a more robust upper airway muscle response compared to patients with OSA, thus allowing them to overcome their mildly collapsible airway. Together, these studies suggest that individuals with a P\text{crit} between −5 and −2 cmH\text{O} are vulnerable to developing OSA, but the influence of nonanatomical contributors to OSA pathogenesis can dictate whether or not OSA develops. Thus, OSA patients with mild upper airway collapsibility are likely to be the most appropriate targets for interventions that modify these nonanatomical traits, such as supplemental oxygen to reduce ventilatory control instability\textsuperscript{20} or hypnotics to increase respiratory arousal threshold.\textsuperscript{21} In support of this concept, we have recently demonstrated that patients who responded (defined by a reduction in the AHI of 50% and an AHI on therapy <10 events/hour) to the combination of both supplemental oxygen and the hypnotic eszopiclone,
had a less collapsible airway (ie, more negative P_{crit}) compared to nonresponders.\textsuperscript{7} Interestingly, mild upper airway collapsibility has also been shown to be predictive of response to anatomically oriented OSA treatments. Recent evidence suggests that patients who are responders to oral appliances also have a less collapsible airway compared to nonresponders.\textsuperscript{5} This finding is not surprising given that these devices decrease upper airway collapsibility, and the extent to which they can improve OSA severity is related to the degree to which collapsibility reduced.\textsuperscript{22} Of note, the data of Schwartz et al.\textsuperscript{6} similarly show that those patients with a lower baseline P_{crit} are more likely to have OSA resolved following weight loss. This notion raises the possibility that mild airway collapsibility may also predict responses to other anatomically oriented OSA treatments which have been shown to reduce P_{crit} such as upper airway surgeries\textsuperscript{23} and sleeping in the lateral position.\textsuperscript{24}

**Clinical Implications**

The inability to easily measure upper airway collapsibility/\textsuperscript{25} P_{crit} in a clinical setting is one of the major factors limiting the adoption of these personalized treatment options into clinical practice. The key implication of our study’s findings is that therapeutic CPAP requirement can be used to categorically approximate a given patient’s degree of upper airway collapsibility. In this way, patients likely to have a mild collapsibility may be identified in a clinically practical way, by using existing titration procedures and standard CPAP equipment.

Although our data are retrospective and require further prospective validation, our proposed CPAP level thresholds demonstrate high specificity and PPV, which would allow clinicians to use this information to “rule in” patients into trial measurement of the other contributing traits responsible for OSA. The key implication of our study’s findings is that therapeutic CPAP requirement can be used to categorically approximate a given patient’s degree of upper airway collapsibility. In this way, patients likely to have a mild collapsibility may be identified in a clinically practical way, by using existing titration procedures and standard CPAP equipment.

Although our data are retrospective and require further prospective validation, our proposed CPAP level thresholds demonstrate high specificity and PPV, which would allow clinicians to use this information to “rule in” patients into trial measurement of the other contributing traits responsible for OSA. The key implication of our study’s findings is that therapeutic CPAP requirement can be used to categorically approximate a given patient’s degree of upper airway collapsibility. In this way, patients likely to have a mild collapsibility may be identified in a clinically practical way, by using existing titration procedures and standard CPAP equipment.

<table>
<thead>
<tr>
<th>CPAP level</th>
<th>Data set</th>
<th>Sens(%)</th>
<th>Spec (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
<th>Acc (%)</th>
<th>TP (n)</th>
<th>TN (n)</th>
<th>FP (n)</th>
<th>FN (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤6.0 cmH\textsubscript{2}O</td>
<td>Development set</td>
<td>67</td>
<td>97</td>
<td>86</td>
<td>92</td>
<td>91</td>
<td>6</td>
<td>36</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Validation set</td>
<td>54</td>
<td>100</td>
<td>100</td>
<td>78</td>
<td>82</td>
<td>15</td>
<td>45</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>≤7.0 cmH\textsubscript{2}O</td>
<td>Development set</td>
<td>89</td>
<td>88</td>
<td>62</td>
<td>97</td>
<td>87</td>
<td>8</td>
<td>32</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Validation set</td>
<td>64</td>
<td>98</td>
<td>95</td>
<td>82</td>
<td>85</td>
<td>18</td>
<td>45</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>≤8.0 cmH\textsubscript{2}O</td>
<td>Development set</td>
<td>89</td>
<td>84</td>
<td>57</td>
<td>97</td>
<td>86</td>
<td>8</td>
<td>31</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Validation set</td>
<td>75</td>
<td>91</td>
<td>84</td>
<td>86</td>
<td>85</td>
<td>21</td>
<td>42</td>
<td>4</td>
<td>7</td>
</tr>
</tbody>
</table>

Acc = accuracy of test; FN = false negative; FP = false positive; NPV = negative predictive value; PPV = positive predictive value; Sens = sensitivity; Spec = specific; TN = true negative; TP = true positive.

Table 3—Comparison of CPAP Cutoff Levels to predict Mild Upper Airway Collapsibility.

Given the complexity of OSA pathophysiology, it is likely that other physiological factors may be important in predicting the likelihood of therapeutic response. For example, although our data suggest that a patient’s therapeutic CPAP level can provide clinicians with an understanding about whether upper airway collapsibility plays a major or relatively minor role in determining why an individual patient develops OSA, it is important to note that this simplified measure does not provide any information about the specific site of airway collapse. This may be an important factor particularly in determining the efficacy of certain non-CPAP therapies.\textsuperscript{28} thus information regarding the therapeutic CPAP level paired with an otorhinolaryngological examination and/or drug-induced endoscopy\textsuperscript{29} may produce a more comprehensive understanding of the propensity toward airway collapse. Furthermore, other nonanatomical pathogenic traits may be important factors contributing to OSA in many individuals, particularly those with mild upper airway collapsibility. Fortunately, recent progress has also been made toward simplified measurement of the other contributing traits responsible for OSA. Terrill et al.\textsuperscript{31} have demonstrated that loop gain (a measure of ventilatory control instability) can be quantified using signals collected routinely in a diagnostic sleep study (EEG, nasal pressure, \textit{SaO}_2, and respiratory effort). In addition, we previously demonstrated that a patient’s arousal threshold can be determined by indices easily obtainable from a diagnostic sleep study report (AHI, nadir oxygen desaturation, and proportion of respiratory events scored as hypopnea compared to apneas).\textsuperscript{32} Although these tools are clinically feasible and promising, future prospective studies are needed to investigate specifically whether this information can prospectively predict treatment response.
The way in which therapeutic CPAP level is determined is likely to be a critical component contributing to the strength of the predictive relationship we have demonstrated between CPAP level and P_{crit}. In the present work, CPAP titration procedures and our definition of the therapeutic CPAP level were based on strict physiological criteria (ie, the minimum pressure capable of eliminating respiratory events and inspiratory flow limitation). Moreover, our therapeutic level and was reassessed/retitrated multiple times to ensure accuracy. It is important for clinicians to carefully consider the specific circumstances and method of CPAP titration performed before attempting to use therapeutic CPAP level data clinically. Given that autotitrating positive airway pressure (APAP) devices use sensitive measurement of flow-limited breathing to titrate pressure, we believe that a therapeutic CPAP level determined from APAP devices (conventionally defined by the 90th/95th percentile pressure statistic) is also likely to predict upper airway collapsibility. It is important to note, however, that differently branded APAP devices are likely to use different algorithms for detecting flow limitation, titrating pressure, and for determining 90th/95th percentile pressure levels. Future prospective work is required to further test the prediction of collapsibility using CPAP level. Such work should investigate how this relationship may change across titration procedures, between manual versus autotitration, and between APAP devices.

Methodological Considerations

When interpreting our findings, there are a number of limitations that must be considered. The current predictive tool was based on data obtained when patients were sleeping in the supine position. It is therefore uncertain whether the relationship between therapeutic CPAP and P_{crit} we have demonstrated is generalizable to patients sleeping in the lateral position. However, given that OSA is often less severe, the upper airway less collapsible, and CPAP level requirements are often reduced in the lateral position, we expect the supine therapeutic CPAP level will be more useful in defining who will respond to non-CPAP therapies in all sleeping positions.

Many participants in the present study were receiving treatment for OSA (via CPAP or oral appliance) before study procedures, and no washout period was required before they underwent the clinical and research PSGs. Given that the AHI has been shown to remain somewhat reduced for a period (~1 week) following the termination of CPAP therapy, our measurement of participant’s AHI may have been underestimated. Importantly, both therapeutic CPAP and upper airway collapsibility appear to be unaffected by this “CPAP washout” effect, and thus, this factor is unlikely to have influenced the reported association between therapeutic CPAP level and P_{crit}.

Of note, the therapeutic CPAP level derived in each of our participants was accomplished specifically in supine, NREM sleep, while determining P_{crit} during a research PSG. It is possible that this CPAP level may differ from values determined during a clinical CPAP titration. In a subset of 27 patients in which we had both measurements, the research PSG derived therapeutic CPAP level (median = 10.7, IQR = 3.07) was slightly higher compared to the physician prescribed CPAP level (median = 10.0, IQR = 4.00, p = .56). However, in each case, the prediction of upper airway collapsibility (mild vs. moderate/severe upper airway collapsibility) was not altered based on whether we used the patient’s prescribed or research determined therapeutic CPAP level.

Conclusions

In summary, our findings show a strong relationship between a patient’s therapeutic CPAP requirement and the underlying severity of upper airway collapsibility. Importantly, we have demonstrated that the therapeutic CPAP level can be used to discriminate between individuals with a mildly collapsible upper airway from those with moderate/severe collapsibility. Although our data need to be confirmed prospectively under different titration conditions, this simple tool has the potential to aid in personalizing the treatment of OSA, by allowing clinicians to screen for and determine which patients are most suitable for individual non-CPAP therapies targeted at treating the underlying causes of OSA.

REFERENCES


SUPPLEMENTARY MATERIAL
Supplementary material is available at SLEEP online.

FUNDING
Dr. Landry is supported by NeuroSleep, a NHMRC Centre of Research Excellence (1060992) as well as the Monash University Faculty of Medicine, Nursing and Health Sciences postdoctoral bridging Fellowship. Dr Eckert is supported by a NHMRC Senior Research Fellowship (1116942). Dr Jordan is supported by the Australian Research Council (FT100203203). Dr. Sands was supported by the American Heart Association (15SDG25890059), National Health and Medical Research Council of Australia (1053201), the Menzies Foundation, American Thoracic Society Foundation, and the National Institute of Health (R01HL128658, ZR01HL102321, P01HL1005080). Dr. Edwards was supported by the National Health and Medical Research Council (NHMRC) of Australia’s CJ Martin Overseas Biomedical Fellowship (1035115) and is now supported by a Heart Foundation of Australia Future Leader Fellowship (101167). Dr. Malhotra is PI on NIH R01HL085188, K24HL132105 and coinvestigator on R21HL121794, R01HL119201, R01HL081823. This work was also supported by Harvard Catalyst (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1TR001102).

ACKNOWLEDGMENTS
The authors would like to thank Lauren Hess, Erik Smales, Pam DeYoung, Alison Foster, Elizabeth Skuza, and Chris Andara for their laboratory assistance.

SUBMISSION & CORRESPONDENCE INFORMATION
Submitted for publication October, 2016
Submitted in final revised form January, 2017
Accepted for publication April, 2017
Address correspondence to: Shane A. Landry, PhD, Sleep and Circadian Medicine Laboratory, Department of Physiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia. Telephone: 613 9905 9767; Fax: 613 9905 3948; Email: shane.landry@monash.edu

DISCLOSURE STATEMENT
As an Officer of the American Thoracic Society, Dr. Malhotra has relinquished all outside personal income since 2012. ResMed, Inc. provided a philanthropic donation to the UC San Diego in support of a sleep center. Dr. White was the chief medical officer for Philips Respironics until 12/31/12 but is now a consultant. Dr White is also the chief scientific officer for Apnicure Inc as of January 2013 and a consultant for Night Balance since 2014. A/Prof Hamilton and Dr Joosten have received equipment to support research from ResMed, Philips Respironics and Air Liquide Healthcare. Dr Sands has worked as a consultant for Cambridge Sound Management. All other authors have no conflicts to disclose and do not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.